Pfizer Inc. (NYSE: PFE) shares sold by Capital Market Strategies LLC

0

Capital Market Strategies LLC reduced its stake in Pfizer Inc. (NYSE: PFE – Get Rating) by 6.3% in the first quarter, according to its latest disclosure to the Securities and Exchange Commission (SEC). The institutional investor held 26,185 shares of the biopharmaceutical company after selling 1,758 shares during the quarter. Pfizer represents 1.2% of Capital Market Strategies LLC’s investment portfolio, making the stock its 18th-highest position. Capital Market Strategies LLC’s holdings in Pfizer were worth $1,356,000 when it last filed with the SEC.

Several other institutional investors also bought and sold shares of the company. OZK Bank increased its position in Pfizer shares by 0.3% in the fourth quarter. OZK Bank now owns 68,883 shares of the biopharmaceutical company valued at $4,067,000 after buying an additional 195 shares last quarter. TimeScale Financial Inc. increased its position in Pfizer shares by 2.9% in the fourth quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company valued at $412,000 after buying 196 additional shares last quarter. Fruth Investment Management increased its position in Pfizer shares by 0.7% in the fourth quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company valued at $1,730,000 after buying an additional 200 shares last quarter. Winfield Associates Inc. increased its position in Pfizer shares by 0.9% in the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company valued at $1,273,000 after buying 200 more shares last quarter. Finally, Birinyi Associates Inc. increased its position in Pfizer shares by 3.4% in the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company valued at $311,000 after buying an additional 200 shares last quarter. Institutional investors and hedge funds hold 66.50% of the company’s shares.

Separately, Executive Vice President William R. Carapezzi, Jr. sold 32,908 shares in a trade dated Thursday, May 12. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares of the company, valued at approximately $1,907,300. The transaction was disclosed in a filing with the SEC, which is available via this hyperlink. Additionally, SVP Jennifer B. Damico sold 4,000 shares in a trade dated Monday, May 16. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the transaction, the senior vice president now directly owns 15,064 shares of the company, valued at approximately $760,732. The disclosure of this sale can be found here. In the past ninety days, insiders have sold 41,126 shares of the company worth $2,075,003. Company insiders hold 0.05% of the company’s shares.

NYSE PFE opened at $50.94 on Thursday. Pfizer Inc. has a fifty-two-week low of $38.82 and a fifty-two-week high of $61.71. The stock’s fifty-day moving average is $50.51 and its two-hundred-day moving average is $52.19. The company has a market cap of $285.82 billion, a P/E ratio of 11.68, a price-to-earnings growth ratio of 0.63, and a beta of 0.76. The company has a debt ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly results on Tuesday, May 3. The biopharmaceutical company reported EPS of $1.62 for the quarter, missing the consensus estimate of $1.66 per ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company posted revenue of $25.66 billion in the quarter, versus analyst estimates of $24.73 billion. During the same period last year, the company achieved EPS of $0.93. The company’s revenue for the quarter increased 76.8% year over year. As a group, sell-side analysts expect Pfizer Inc. to post EPS of 6.61 for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Wednesday, June 29 will receive a dividend of $0.40. This represents an annualized dividend of $1.60 and a dividend yield of 3.14%. The ex-dividend date is Thursday July 28. Pfizer’s dividend payout ratio (DPR) is currently 36.70%.

A number of analysts have recently commented on the company. Goldman Sachs Group set a price target of $51.00 on Pfizer in a research report on Wednesday, May 25. Barclays set a price target of $52.00 for Pfizer in a research report on Monday. Berenberg Bank set a price target of $50.00 on Pfizer in a research report on Friday, May 27. Citigroup raised its price target on Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a Tuesday, April 5 research report. Finally, SVB Leerink began covering Pfizer in a research report on Monday, May 23. They set a “market performance” rating and a price target of $55.00 for the company. Nine equity research analysts gave the stock a hold rating, ten gave the stock a buy rating and one gave the stock a strong buy rating. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.26.

About Pfizer (Get an assessment)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.

Featured articles

Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional ownership by quarter for Pfizer (NYSE:PFE)



Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

About Author

Comments are closed.